THEUNITEDREPUBLICOFTANZANIA

MINISTRY OF HEALTH

TANZANIA MEDICINES AND MEDICAL DEVICES AUTHORITY

PUBLIC ASSESSMENT REPORT FOR PREZEL 75 (PREGABALIN 75 MG) HARD GELATIN CAPSULES

Version number 01

03/01/2023

TMDA Headquarters, Plot No. 56/1, Block E, Kisasa B Centre, Swaswa Road, P. O. Box 1253, Dodoma – Tanzania, Telephone: +255 (26) 2961989/2061990/+255 (22) 2450512/2450751/2452108, Email: info@tmda.og.tz, Website: **www.tmda.go.tz**

Toll free: 0800110084

1. Introduction

Prezel 75 is a generic medicine of Lyrica 75 mg hard capsules of Pfizer Limited, is an analogue of the neurotransmitter gamma-aminobutyric acid (GABA). Pregabalin decreases central neuronal excitability by binding to an auxiliary subunit (α2-δ protein) of a voltage-gated calcium channel on neurons in the central nervous system. Pregabalin reduces the release of several neurotransmitters, including glutamate, noradrenaline, and substance. Prezel 75 is approved in Tanzania for use only in adult patients.

1.1 Product details

Registration number	TAN 22 HM 0161
Brand name	Prezel 75
Generic name, strength, and form	Each hard gelatin capsule contains 75 mg Pregabalin
ATC classification	ATC Code- N03AX16 (Anti–epileptics, other antiepileptics)
Distribution category	POM
Country of origin	India
Associated product	Prezel 150
Marketing Authorization Holder	Ind-Swift Limited Off. NH-21, Village Jawaharpur, Tehsil Derabassi, Distt. SAS Nagar (Mohali), Punjab 140507, India
Local Technical Representative	Planet Pharmaceuticals Limited P. O. Box 38328, Dar es Salaam

1.2 Assessment procedure

The application for registration of Prezel 75 was submitted on 20/05/2020. The product underwent full assessment. Assessment was completed in 3 (three) rounds of evaluation and the product was registered on 20/08/2021.

1.3 Information for users

Visual description of the finished product	Size '4' hard gelatin capsules, reddish brown cap with creamish color body
Primary packing material	Blister strips [composed of Rigid PVC film coated with PVdC Pharma grade (clear, 90gsm coated) and Printed Aluminium Foil]
Secondary packing materials	A printed carton box
Shelf-life and storage condition	24 months, Do not store above 30^{o}C Protect from moisture
Route of administration	Oral
Therapeutic indications	- Neuropathic pain Pregabalin is indicated for the treatment of peripheral and central neuropathic pain in adults.

	- Epilepsy Pregabalin is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. - Generalised Anxiety Disorder Pregabalin is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults

2. Labelling and product information

Summary of product characteristics
The SmPC included all the relevant information to ensure correct and safe use of the medicine by healthcare providers. The complete SmPC can be accessed here.

Package insert/leaflet
The package insert is confirmed to be derived from the SmPC and contains sufficient data for the end user. Since the product is POM, the package insert contains full prescribing information as per SmPC.

Container labels
The product label information is presented in English. Details in the secondary pack label include:
Brand name: Prezel 75

Composition: Each Hard gelatin capsule contains 75 mg Pregabalin

Pack size:3x10 capsules

Manufacturing details: batch number, manufacturing date, and expiry date

Storage conditions: Do not store above 30^{o}C. Protect from moisture

Manufacturer address: physical address of release site

Unique identifier: Not applicable

Special warnings/precautions or instructions for use: Read the patient information leaflet before use

The details of the primary pack include:

Brand name and strength: Prezel 75 (Each hard gelatin capsule contains 75 mg Pregabalin)

Manufacturing details: batch number, manufacturing date and expiry date

Name of manufacturer: Ind-Swift Limited
The content of the primary and secondary labels was aligned to the requirements of the Part V of the Compendium: Guidelines on Format and Content of Product Labels for Medicinal products. The label contains sufficient information for proper identification of the medicine and post marketing follow up of the product.

Mock labels are appended as annex I.

3. Scientific discussion

Quality of Active Pharmaceutical Ingredients

Information on the quality of the API was submitted in form of DMF.

General Information

Pregabalin API is compendia in USP, Ph.Eur. and BP.

Molecular formula: $C_8H_{17}NO_2$

Chemical name:
(3S)-3-(Aminomethyl)-5-methylhexanoic acid

Structure:



General properties

Pregabalin is a white to off-white, non-hygroscopic, crystalline powder, slightly soluble in water and methanol. The drug substance exhibits polymorphism. Form I is manufactured. The drug substance shows isomerism. The drug substance corresponds to the S-enantiomer. A test for the enantiomeric purity is included in the drug substance specification.

Pregabalin drug substance falls into the category of BCS class I, being a highly soluble and highly permeable compound, therefore polymorphism and PSD are not critical parameters for performance of this drug product.

Manufacture

Pregabalin API manufacturer is Zhejiang Huahai Pharmaceutical Co., Ltd, Chuannan, Duqiao, Linhai, Zhejiang Province-317 016, China. The manufacturing complies with GMP requirements as evidenced by the GMP certificate issued by the Zhejiang Food & Drug Administration, China. Pregabalin API is manufactured by chemical synthesis using conventional techniques. Sufficient controls of quality of materials and in-process checks were employed throughout the manufacturing process.

Specifications

The API specifications were set as per Ph.Eur. standards and ICHQ3A. The parameters monitored during quality control are: Appearance (visual inspection), solubility, identity (IR and

HPLC), assay (HPLC), water content, enantiomeric purity, other related impurities (HPLC), sulfated ash, residual solvents (GC), bulk density, and tapped density. Compliance to these specifications were established via batch analysis data and stability studies.

Stability and container closure system

The re-test period of Pregabalin API is 36 months when packed in the original container with no specific storage conditions.

Quality of the Finished Pharmaceutical Product

Formulation

Prezel 75 is a size '4' hard gelatin capsules, reddish brown cap with creamish color body

Prezel 75 contains the Pregabalin and other ingredients listed here after: Pregelatinised Starch, Talc and Capsule Size # 4 (Titanium Dioxide, Gelatin and Sodium Lauryl Sulphate). The quantities of all ingredients are confirmed to be in line with the recommendations of Handbook of Pharmaceutical Excipients, 8th Edition in terms of function and quantities.

Manufacture

The finished product manufacturer is Ind-Swift Limited, Off. NH-21, Village Jawaharpur, Tehsil Derabassi,Distt. SAS Nagar (Mohali), Punjab 140507, India. The compliance of the site to TMDA GMP standards was confirmed through site inspection on 19/10/2018.
.

Specifications

The FPP is compendia in BP. The manufacturer controls the quality of the finished product as per in-house standards and ICH requirements. The parameters monitored during quality control are: appearance (visual inspection), identification (HPLC, IR), disintegration, water content, average fill mass, fill mass variation, dissolution, uniformity of dosage unit by mass variation, assay (HPLC), impurities (HPLC), and microbial content. Compliance to the standard was established using batch analysis data and stability data.

Stability and container closure system

Stability studies were conducted on 3(three) batches of the finished product stored at 30 ± 2°C & RH: 75 ± 5% RH for 24months and 40± 2°C & RH: 75% ± 5% RH for 6 months. Based on the stability data presented, the approved shelf-life is 36 months when stored in blister strips [composed of Rigid PVC film coated with PVdC Pharma grade (clear, 90gsm coated) and Printed Aluminium Foil] with storage condition ‘Do not store above 30^{o}C. Protect from moisture’.

Safety and efficacy information

The biowaiver was approved based on additional strength.

Prezel 75 fulfilled the criteria for waiving an in-vivo bioequivalence study as per relevant TMDA guidance. Dissolution profiles of Prezel 75 mg, capsule was compared to Prezel 300 mg, capsule. At least 85% of the labelled amount of Pregabalin had dissolved in all three media. Therefore, confirming similarity.

4. Benefit-Risk Assessment and Conclusion

On basis of the data submitted, the current state of knowledge and compliance to Good Manufacturing Practice, the benefit of the product outweighs the risks associated with its use when used in accordance to the summary of product characteristics. Prezel 75 is recommended for registration.

5. Benefit-Risk Assessment and Conclusion

On basis ofthe data submitted, the current state of knowledge and compliance to Good Manufacturing Practice, the benefit of the product outweighs the risks associated with its use when used in accordance to the summary of product characteristics. Prezel 75 is recommended for registration.

6. Post-approval updates

Variation applications

Reference number	Date submitted	Change requested	Recommendation	Granting date

Feedback from pharmacovigilance, post marketing surveillance and enforcement activities

Type of feedback	Impact	Response

Re-registration applications

Application for renewal of registration was submitted on <DDMMYYYY>. The application was finalized in <number> rounds of evaluation. The product was confirmed to still be compliant to

the standards of quality, safety and efficacy, hence registration was renewed on <DDMMYYYY>.

PART 5: CHANGE HISTORY

Version number	Date	Description of update	Section(s) Modified	Approval date

Annex I: Mock up label

Primary label:



Secondary label